FN Archimer Export Format
PT J
TI Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab
BT 
AF MAILLET, A
   CONGY JOLIVET, N
   LE GUELLEC, S
   VECELLIO, L
   HAMARD, S
   COURTY, Y
   COURTOIS, Anthony
   GAUTHIER, F
   DIOT, P
   THIBAULT, G
   LEMARIE, E
   HEUZE VOURC' H, N
AS 1:1;2:2,3;3:4;4:1;5:1;6:1;7:5,6;8:1;9:1,3;10:2,3;11:1,3;12:1,7;
FF 1:;2:;3:;4:;5:;6:;7:;8:;9:;10:;11:;12:;
C1 Univ Tours, U618, Tours, France.
   Univ Tours, UPRES EA 3853, IPGA, Tours, France.
   CHRU Tours, F-37000 Tours, France.
   DTF, Atomisor, F-42003 St Etienne, France.
   Univ Bretagne Occidentale, Lab Therapie Cellulaire & Immunobiol Canc, CHU Morvan Brest, Brest, France.
   IFREMER, Lab Biotechnol & Mol Marines, Plouzane, France.
   Fac Med, INSERM, U618, F-37032 Tours, France.
C2 UNIV TOURS, FRANCE
   UNIV TOURS, FRANCE
   CHRU TOURS, FRANCE
   DTF, FRANCE
   UBO, FRANCE
   IFREMER, FRANCE
   UNIV TOURS, FRANCE
SI BREST
SE PDG-DOP-DCB-BM-BMM
IN WOS Ifremer jusqu'en 2018
   copubli-france
   copubli-univ-france
IF 4.024
TC 39
UR https://archimer.ifremer.fr/doc/2008/publication-4201.pdf
LA English
DT Article
DE ;Nebulizer;Lung cancer;Cetuximab;Anticancer antibody;Aggregation;Aerosol
AB Purpose. Despite an increasing interest in the use of inhalation for local delivery of molecules for respiratory diseases and systemic disorders, methods to deliver therapy through air-ways has received little attention for lung cancer treatment. However, inhalation of anticancer drugs is an attractive alternative route to systemic administration which results in limited concentration of the medication in the lungs, and triggers whole-body toxicity. In this study, we investigated the feasibility of nebulization for therapeutic antibodies, a new class of fully-approved anticancer drugs in oncology medicine.   Materials and methods. Cetuximab, a chimeric IgG1 targeting the epidermal growth factor receptor (EGER), was nebulized using three types of delivery devices: a jet nebulizer PARI LC+(R), a mesh nebulizer AeronebPro (R) and an ultrasonic nebulizer SYST'AM (R) LS290. Aerosol size distribution was measured using a cascade impactor and aerosol droplets were observed under optical microscopy. The immunological and pharmacological properties of cetuximab were evaluated following nebulization using A431 cells.   Results. The aerosol particle clouds generated with the three nebulizers displayed similar aerodynamical characteristics, but the IgG formed aggregates in liquid phase following nebulization with both the jet and ultrasonic devices. Flow cytometry analyses and assays of EGFR-phosphorylation and cell growth inhibitions on A431 demonstrated that both the mesh and the jet nebulizers preserved the binding affinity to EGER and the inhibitory activities of cetuximab.   Conclusions. Altogether, our results indicate that cetuximab resists the physical constraints of nebulization, Thus, airway delivery represents a promising alternative to systemic administration for local delivery of therapeutic antibodies in lung cancer treatment.
PY 2008
PD JUL
SO Pharmaceutical Research
SN 0724-8741
PU Springer
VL 25
IS 6
UT 000255753900007
BP 1318
EP 1326
DI 10.1007/s11095-007-9481-3
ID 4201
ER

EF